Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to evaluate the metabolomic profile of MM patients to identify those at high risk prior to carfilzomib treatment and to explore the mechanisms of carfilzomib-CVAE to inform potential strategies to protect patients from this cardiotoxicity. Global metabolomic profiling was performed on the baseline and post-baseline plasma samples of 60 MM patients treated with carfilzomib-based therapy, including 31 who experienced CVAE, in a prospective cohort study. Baseline metabolites and post-baseline/baseline metabolite ratios that differ between the CVAE and no-CVAE patients were identified using unadjusted and adjusted methods. A baseline metabolomic risk score was created to stratify patients. We observed a lower abundance of tauroursodeoxycholic acid (T-UDCA) in CVAE patients at baseline (odds ratio [OR] = 0.47, 95% confidence interval [CI] = 0.21-0.94, p = 0.044) compared with the no-CVAE patients. A metabolite risk score was able to stratify patients into three risk groups. The area under the receiver-operating curve of the model with clinical predictors and metabolite risk score was 0.93. Glycochenodeoxycholic acid (OR = 0.56, 95% CI = 0.31-0.87, p = 0.023) was significantly lower in post-baseline/baseline ratios of CVAE patients compared with no-CVAE patients. Following metabolomic analysis, we created a baseline metabolite risk score that can stratify MM patients into different risk groups. The result also provided intriguing clues about the mechanism of carfilzomib-CVAE and potential cardioprotective strategies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma
- Date Crossref
- 01/05/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
American Association of Colleges of Pharmacy pays non établi dans la noticeInstitution
-
University of Florida Department of Pharmacotherapy and Translational Research Center for Pharmacogenomics and Precision Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University of North Carolina at Chapel Hill Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University of Pennsylvania Division of Cardiology pays non établi dans la noticeUniversité ou école supérieure
-
Moffitt Cancer Center Department of Malignant Hematology pays non établi dans la noticeÉtablissement de santé
-
Saint Francis Medical Center Cape Cardiology Group pays non établi dans la noticeÉtablissement de santé
-
Vanderbilt University Medical Center Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
University of Florida Health pays non établi dans la noticeUniversité ou école supérieure
-
Florida College pays non établi dans la noticeUniversité ou école supérieure
-
UF Health Cancer Center pays non établi dans la noticeÉtablissement de santé
-
College of Pharmacy Department of Pharmacotherapy and Translational Research pays non établi dans la noticeUniversité ou école supérieure
-
Division of Hematology University of North Carolina Chapel Hill North Carolina USA Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
American Association of Colleges of Pharmacy, Department of Pharmacotherapy and Translational Research Center for Pharmacogenomics and Precision Medicine — University of Florida et Department of Medicine — University of North Carolina at Chapel Hill, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.